A carregar...
CNOT4 enhances the efficacy of anti‐PD‐1 immunotherapy in a model of non‐small cell lung cancer
The use of immune checkpoint inhibitors that target programmed cell death‐1 (PD‐1) has been proposed for the treatment of advanced non‐small cell lung cancer (NSCLC). However, in clinical trials, cumulative response rates to anti‐PD‐1 treatment were approximately 20% in patients with NSCLC. CCR4‐NOT...
Na minha lista:
| Publicado no: | FEBS Open Bio |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
John Wiley and Sons Inc.
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7714061/ https://ncbi.nlm.nih.gov/pubmed/33034149 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/2211-5463.12998 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|